Home About Us Pipeline News Investors Contacts Careers

Puma Biotechnology, Inc. Corporate Fact Sheet


RECENT NEWSEVENTSCLINICAL TRIALS



必威体育首页注册检测 - Puma Biotechnology Reports Second Quarter 2019 Financial Results
Read

必威体育首页下载下载

必威体育首页官方二维码 - Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results
Read

必威体育首页官方 - Puma Biotechnologys Licensing Partner Knight Therapeutics Receives Regulatory Approval from Health Canada to Commercialize NERLYNX (neratinib) for Extended Adjuvant Treatment of Hormone Receptor Positive, HER2-Positive Early Stage Breast Cancer
Read

必威体育首页客户端检测 - Puma Biotechnology Presents Interim Results from the Biliary Tract Cohort of its Phase II SUMMIT Basket Trial of Neratinib at the ESMO World Congress on Gastrointestinal Cancer 2019
Read

必威体育首页娱乐官网 - Puma Biotechnology Submits a Supplemental New Drug Application to U.S. FDA for Neratinib to Treat HER2-Positive Metastatic Breast Cancer
Read

必威体育首页下载首页 - Puma Biotechnology Presents Results from Phase III NALA Trial of Neratinib in Patients with HER2 Positive Metastatic Breast Cancer at the ASCO 2019 Annual Meeting
Read

必威体育首页二维码娱乐 - Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the ASCO 2019 Annual Meeting
Read

必威体育首页app首页 - Puma Biotechnology to Present at Jefferies 2019 Global Healthcare Conference
Read

必威体育首页app首页 - Puma Biotechnology Reports First Quarter 2019 Financial Results
Read

必威体育首页地址线路 - Puma Biotechnology to Present at Bank of America Merrill Lynch Health Care Conference 2019
Read

必威体育首页注册检测 - Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial Results
Read

必威体育首页客户端检测 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read

必威体育首页下载网址 - Puma Biotechnology Expands Cohorts in Phase II SUMMIT Trial of Neratinib in Cancer Patients with Tumors with Activating EGFR or HER2 Mutations
Read

必威体育首页线路线路 - Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX (neratinib) in Europe
Read

必威体育首页客户端检测 - Puma Biotechnology Announces Publication of Abstracts on Neratinib for AACR Annual Meeting 2019
Read

必威体育首页二维码软件 - Puma Biotechnology Presents Interim Results from the Phase II SUMMIT Trial of Neratinib for HER2 (ERBB2) Mutant, Metastatic Cervical Cancer at the Society of Gynecologic Oncology (SGO) 2019 Annual Meeting - Oral Plenary Presentation Receives SGO Presidential Award
Read

必威体育首页地址线路 - Puma Biotechnologys Licensing Partner Specialised Therapeutics Asia Receives Regulatory Approval to Commercialize NERLYNX (neratinib) for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer
Read

必威体育首页二维码娱乐 - Puma Biotechnology to Present at Cowens Annual Health Care Conference
Read

必威体育首页首页二维码 - Puma Biotechnology Reports Fourth Quarter and Full Year 2018 Financial Results
Read

必威体育首页二维码软件 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read

必威体育首页下载首页 - Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results
Read

必威体育首页客户端检测 - Puma Biotechnology Announces Litigation Victory with Jurys Decision
Read


必威体育首页娱乐官网 - Puma Biotechnology 2Q-2019 Financial Results Conference Call
More

必威体育首页app注册

必威体育首页下载下载 - ESMO 2019 Annual Meeting
More

必威体育首页娱乐官网 - ASCO 2019 Annual Meeting
More

必威体育首页地址线路 - Jefferies 2019 Global Healthcare Conference
More

必威体育首页官方二维码 - Bank of America Merrill Lynch 2019 Health Care Conference
More

必威体育首页ios软件 - Puma Biotechnology 1Q-2019 Financial Results Conference Call
More

必威体育首页ios软件 - AACR Annual Meeting 2019
More

必威体育首页下载网址 - Society of Gynecologic Oncology (SGO) 2019 Annual Meeting
More

必威体育首页二维码软件 - Cowen and Company 39th Annual Health Care Conference
More

必威体育首页app注册 - Puma Biotechnology 4Q-2018 Financial Results Conference Call
More

必威体育首页娱乐官网 - Guggenheim Healthcare Talks Idea Forum, Oncology Day
More

必威体育首页客户端检测 - JP Morgan 37th Annual Healthcare Conference
More

Puma-Sponsored Trials
Investigator-Sponsored Trials




Annual Report

2018 Annual Report

 Annual Report Archives

Contact

必威体育首页app注册
10880 Wilshire Blvd., Suite 2150
Los Angeles, CA 90024
424-248-6500 Main
424-248-6501 Fax

必威体育首页app首页
1-844-MED-PUMA (1-844-633-7862), or
medinfo@

必威体育首页二维码软件
info@

必威体育首页ios软件
ir@